Coloplast A/S (OTCMKTS:CLPBY) Share Price Passes Below Fifty Day Moving Average – Here’s Why

Coloplast A/S (OTCMKTS:CLPBYGet Free Report) crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $10.88 and traded as low as $9.95. Coloplast A/S shares last traded at $9.95, with a volume of 203,967 shares trading hands.

Analyst Ratings Changes

A number of research analysts recently weighed in on CLPBY shares. Royal Bank of Canada upgraded shares of Coloplast A/S from a “hold” rating to a “moderate buy” rating in a report on Monday, March 3rd. UBS Group raised shares of Coloplast A/S from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, Sanford C. Bernstein upgraded shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 28th.

Read Our Latest Research Report on Coloplast A/S

Coloplast A/S Stock Performance

The company has a quick ratio of 0.66, a current ratio of 1.02 and a debt-to-equity ratio of 0.92. The stock has a 50 day simple moving average of $10.88 and a two-hundred day simple moving average of $11.78.

Coloplast A/S (OTCMKTS:CLPBYGet Free Report) last issued its earnings results on Tuesday, February 4th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.01). Coloplast A/S had a return on equity of 28.60% and a net margin of 17.81%. As a group, analysts anticipate that Coloplast A/S will post 0.31 earnings per share for the current fiscal year.

Coloplast A/S Company Profile

(Get Free Report)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.

See Also

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.